Steven Cohen's UTHR Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 186,164 shares of United Therapeutics Corporation (UTHR) worth $90.71 M, representing 0.10% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 29 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in UTHR, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2020, adding 579,148 shares. Largest reduction occurred in Q4 2019, reducing 640,243 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +86,380 | Add 86.57% | 186,164 | $487.25 |
| Q3 2025 | +99,784 | New Buy | 99,784 | $419.21 |
| Q2 2024 | -162,700 | Sold Out | 0 | $0.00 |
| Q1 2024 | +162,700 | New Buy | 162,700 | $229.72 |
| Q4 2023 | -1,037 | Sold Out | 0 | $0.00 |
| Q3 2023 | -10,863 | Reduce 91.29% | 1,037 | $225.87 |
| Q2 2023 | +11,900 | New Buy | 11,900 | $220.75 |
| Q3 2022 | -19,815 | Sold Out | 0 | $0.00 |
| Q2 2022 | -177,285 | Reduce 89.95% | 19,815 | $235.63 |
| Q1 2022 | -10,100 | Reduce 4.87% | 197,100 | $179.41 |
| Q4 2021 | +300 | Add 0.14% | 207,200 | $216.08 |
| Q3 2021 | -345,500 | Reduce 62.55% | 206,900 | $184.58 |
| Q2 2021 | +552,400 | New Buy | 552,400 | $179.41 |
| Q1 2021 | -343,201 | Sold Out | 0 | $0.00 |
| Q4 2020 | -97,326 | Reduce 22.09% | 343,201 | $151.79 |
| Q3 2020 | +171,218 | Add 63.58% | 440,527 | $101.00 |
| Q2 2020 | -309,839 | Reduce 53.50% | 269,309 | $121.00 |
| Q1 2020 | +579,148 | New Buy | 579,148 | $94.83 |
| Q4 2019 | -640,243 | Sold Out | 0 | $0.00 |
| Q3 2019 | +180,803 | Add 39.35% | 640,243 | $79.75 |
| Q2 2019 | +459,440 | New Buy | 459,440 | $78.06 |
| Q1 2019 | -133,643 | Sold Out | 0 | $0.00 |
| Q4 2018 | +133,643 | New Buy | 133,643 | $108.90 |
| Q3 2018 | -2,776 | Sold Out | 0 | $0.00 |
| Q2 2018 | -1,336 | Reduce 32.49% | 2,776 | $113.11 |
| Q1 2018 | -187,887 | Reduce 97.86% | 4,112 | $112.35 |
| Q4 2017 | +191,999 | New Buy | 191,999 | $147.95 |
| Q4 2014 | -8,700 | Sold Out | 0 | $0.00 |
| Q3 2014 | +8,700 | New Buy | 8,700 | $128.62 |
Steven Cohen's United Therapeutics Corporation Investment FAQs
Steven Cohen first purchased United Therapeutics Corporation (UTHR) in Q3 2014, acquiring 8,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held United Therapeutics Corporation (UTHR) for 29 quarters since Q3 2014.
Steven Cohen's largest addition to United Therapeutics Corporation (UTHR) was in Q1 2020, adding 579,148 shares worth $54.92 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 186,164 shares of United Therapeutics Corporation (UTHR), valued at approximately $90.71 M.
As of the Q4 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 0.10% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in United Therapeutics Corporation (UTHR) was 640,243 shares, as reported at the end of Q3 2019.